drugset
drugset / Trial / NCT03131141

A Study to Assess Mass Balance Recovery, Metabolite Profile and Identification of IV and Oral 14C-BC-3781

NCT03131141 ↗

Phase 1 Completed 10 enrolled Nabriva Therapeutics AG Quotient Clinical · collab
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This is a single-centre, open-label, non-randomized, single dose study in healthy male subjects designed to assess mass balance recovery, metabolite profile and metabolite identification of radio-labeled BC-3781 administered via the intravenous or oral routes.

Timeline

Start
2017-01-08
Primary completion
2017-10-09
Completion
2018-03-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Lefamulin Other / unclassified 150 mg Intravenous
Subject Lefamulin Other / unclassified 600 mg Intravenous

Indications

No indication recorded.